DDInter625 DDInter782
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain. It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Elagolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osilodrostat
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Rifampicin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Elagolix may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Elagolix may lead to a major life threatening interaction when taken with Rifampicin
Elagolix may lead to a major life threatening interaction when taken with Tazemetostat